Updated: 07 Jan 2001
1 Kps. enth.: Tanninalbuminat 250 mg.
This Knowledge Centre is intended for allergists, immunologists, dermatologists and other healthcare professionals involved in the treatment and management of Chronic Spontaneous Urticaria (CSU). In the Knowledge Centre, you will find a disease overview, symposium highlights platform, video channel and additional resources including an events calendar and useful external links. This resource has been given a whole new look and feel, intended to improve accessibility and visual appeal. Recent content additions include a frequently asked questions section, case studies from urticaria experts Professor Christian Vestergaard and Professor Torsten Zuberbier and information on the TARGET My Hives app.
The Lysosomal Acid Lipase (LAL) Deficiency Knowledge Centre contains a range of accurate, informative clinical content for healthcare professionals. The disease awareness section presents epidemiology, pathophysiology and diagnosis information, among others. The treatment section details the drug characteristics, safety and efficacy of sebelipase alfa – the first and only licenced treatment for LAL deficiency. The resources section contains further clinical content including a video channel presenting expert opinions on diagnostic approach and current prognosis.
Developed by EPG Health Media (Europe) Ltd for epgonline.org, in collaboration and with content provided by Alexion Pharma GmbH
Gelatine, Farbstoffe E 171, E 172.
Zus.: 1 Tbl. enth.: Tanninalbuminat 500 mg.
Weit. Bestandteile: Gelatine, hochdisperses Siliciumdioxid, Stearinsäure.
Überempfindlichkeit gegenüber Ovalbuminanteil.
Strenge Ind.-Stellung in den ersten 3 Mon. Gr 2 .
See disease awareness facts and stats, information on sebelipase alfa (the first and only licensed treatment for LAL-D) and resources section, including expert video channel…